Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLRB NASDAQ:INNT OTCMKTS:MCUJF NASDAQ:VVUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$4.88-1.0%$8.18$4.36▼$94.50$8.92M0.51144,618 shs61,373 shsINNTInnovate Biopharmaceuticals$0.97$0.37▼$1.67$8K-0.39525,982 shs18 shsMCUJFMedicure$0.86$0.79$0.44▼$0.94$8.99M1.06575 shsN/AVVUSVIVUS$0.37$0.44▼$4.75$7.33M-0.841.44 million shs2.03 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences-1.01%+1.22%-61.89%-41.74%-93.08%INNTInnovate Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%MCUJFMedicure0.00%-5.48%-0.18%+59.53%-4.28%VVUSVIVUS0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLRBCellectar Biosciences3.5196 of 5 stars3.25.00.00.02.71.71.3INNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMCUJFMedicureN/AN/AN/AN/AN/AN/AN/AN/AVVUSVIVUSN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLRBCellectar Biosciences 2.33Hold$375.007,584.43% UpsideINNTInnovate Biopharmaceuticals 0.00N/AN/AN/AMCUJFMedicure 0.00N/AN/AN/AVVUSVIVUS 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CLRB, MCUJF, INNT, and VVUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025CLRBCellectar BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLRBCellectar BiosciencesN/AN/AN/AN/A$8.98 per shareN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/A($0.27) per shareN/AMCUJFMedicure$15.99M0.56$0.09 per share9.66$1.45 per share0.59VVUSVIVUS$69.76M0.00N/AN/A($6.50) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLRBCellectar Biosciences-$44.58M-$21.92N/AN/AN/AN/A-619.70%-158.04%8/13/2025 (Estimated)INNTInnovate Biopharmaceuticals-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/AMCUJFMedicure-$760K-$0.13N/A∞N/A-8.15%-8.74%-6.05%8/12/2025 (Estimated)VVUSVIVUS-$31.50M-$2.96N/AN/AN/A-39.28%N/A-12.18%N/ALatest CLRB, MCUJF, INNT, and VVUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025MCUJFMedicureN/A-$0.05N/A-$0.05N/A$3.82 million5/13/2025Q1 2025CLRBCellectar Biosciences-$5.10-$3.90+$1.20-$0.14N/AN/A4/25/2025Q4 2024MCUJFMedicureN/A-$0.04N/A-$0.04N/A$4.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLRBCellectar BiosciencesN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AMCUJFMedicureN/AN/AN/AN/AN/AVVUSVIVUSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLRBCellectar BiosciencesN/A2.472.47INNTInnovate BiopharmaceuticalsN/A0.350.35MCUJFMedicure0.021.711.29VVUSVIVUSN/A0.430.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLRBCellectar Biosciences16.41%INNTInnovate Biopharmaceuticals5.88%MCUJFMedicureN/AVVUSVIVUS7.32%Insider OwnershipCompanyInsider OwnershipCLRBCellectar Biosciences5.04%INNTInnovate Biopharmaceuticals7.90%MCUJFMedicure12.90%VVUSVIVUS12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLRBCellectar Biosciences101.81 million1.72 millionOptionableINNTInnovate Biopharmaceuticals841.33 millionN/ANot OptionableMCUJFMedicureN/A10.44 million9.09 millionNot OptionableVVUSVIVUS5717.87 millionN/AOptionableCLRB, MCUJF, INNT, and VVUS HeadlinesRecent News About These CompaniesVIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin LymphomaApril 14, 2025 | globenewswire.comVIVUS' QSYMIA® to be Featured on Health Uncensored with Dr. DrewMarch 19, 2025 | globenewswire.comVIVUS Launches QSYMIA® in the United Arab EmiratesMarch 10, 2025 | globenewswire.comVIVUS Unveils Global Initiative to Advance Healthy and Sustainable Weight ManagementMarch 4, 2025 | globenewswire.comVIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025January 13, 2025 | globenewswire.comVIVUS Shares Significant Regulatory Update on QSYMIA®October 28, 2024 | globenewswire.comVIVUS Announces Label Update for QSYMIA®October 23, 2024 | tmcnet.comGeorgia rapper pleads guilty to federal gang, drug charges; asked for gun at movie theaterAugust 16, 2024 | wsbtv.comWVIVUS Provides Update on Pipeline and Program MilestonesJanuary 8, 2024 | markets.businessinsider.comShark research group to build new global headquarters in Jacksonville with help from state fundingJune 26, 2023 | actionnewsjax.comAMetaview announces Answers, the world's first conversational AI for the interview processMay 25, 2023 | it.tmcnet.comPancrelipase (CAS 53608-75-6) Market 2023 | Industry Growth ... - StreetBuzzMay 12, 2023 | news.google.comNExploring Huge Demand of Peripherally Acting Anti-Obesity Drug ... - Digital JournalMay 12, 2023 | news.google.comNExtensive Growth Opportunities to be Witnessed by Prescription Weight-Loss Pills Market 2023 Analysis of Risin - openPRMay 11, 2023 | news.google.comNErectile Dysfunction Drugs Market to Register High Demand Rate by ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comNMilestone Pharmaceuticals Reports First Quarter 2023 Financial ... - PR NewswireMay 11, 2023 | news.google.comNAnti-obesity Therapeutics Market to Witness the Highest Growth ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comNAnti Obesity Drugs Market Future Industry Scope for New ... - Digital JournalMay 11, 2023 | news.google.comNThis Crazy Six-Wheel Hatchback by Briggs & Stratton Was One of ... - autoevolutionMay 10, 2023 | news.google.comNProstatic Artery Embolization Market Current and Upcoming Projects ... - Digital JournalMay 9, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLRB, MCUJF, INNT, and VVUS Company DescriptionsCellectar Biosciences NASDAQ:CLRB$4.88 -0.05 (-1.01%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$4.89 +0.01 (+0.12%) As of 07/11/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Innovate Biopharmaceuticals NASDAQ:INNTInnovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.Medicure OTCMKTS:MCUJF$0.86 0.00 (0.00%) As of 07/10/2025Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.VIVUS NASDAQ:VVUSVIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
